Today: 23 June 2026
Browse Category

Pharmaceuticals 14 May 2026 - 9 June 2026

AbbVie is acquiring Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal is expected to close in the third quarter and will bring AbbVie zumilokibart, an experimental long-acting drug for atopic dermatitis and other immune diseases. Apogee claims its top eczema drug could significantly reduce injection frequency compared to Dupixent, with Phase 3 trials planned for this year. Pfizer shares declined over the past week after CFO Dave Denton announced he will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession, execution, and competition from obesity-drug makers. Pfizer’s stock has also been affected by concerns over pricing pressure, patent cliffs, and a longer path to profitability in obesity drugs. Meanwhile, Novo Nordisk shares rose about 5% as healthcare stocks gained favor among investors seeking defensive positions, even as the company reported strong demand for its Wegovy pill. Alumis shares surged 15.55% ahead of Phase 2b lupus results due in the third quarter and a planned psoriasis NDA filing in the fourth quarter. Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected on July 29. Other notable moves include AtaiBeckley’s 7.8% rise following the start of its BPL-003 Phase 3 program and CervoMed’s premarket jump after a director-linked trust purchased $3 million in units, following a recent $10.5 million private placement.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
9 June 2026
··
Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly shares hit a record $1,131.42 close Friday, up 0.6%, after late-stage data showed its experimental retatrutide cut sleep apnea severity by 60.6% and knee osteoarthritis pain by up to 73.1% in obese adults; investors will watch Monday’s trade to see if the new results justify Lilly’s premium as the S&P 500 tumbled 2.64% Friday and rivals like Roche posted strong obesity-drug data.
6 June 2026
···
Merck Stock Gains as Keytruda Concerns Ease, Investors Look to Pipeline Bets

Merck Stock Gains as Keytruda Concerns Ease, Investors Look to Pipeline Bets

Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in Merck’s post-Keytruda pipeline as investors weigh looming patent expirations and competition, with the stock’s rally fueled by optimism but tempered by risks of future trial and regulatory outcomes.
4 June 2026
··
Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer Stock Had a Quiet Week. Its Cancer Pipeline Just Got Loud

Pfizer faces a key market test Monday after unveiling new cancer drug data at ASCO and a China partnership worth up to $10.5 billion. Friday’s close: $26.18, up 0.15%. Braftovi nearly doubled progression-free survival in metastatic colorectal cancer; Talzenna plus Xtandi cut prostate cancer risk by 52%. Seven-year Lorbrena data showed 55% of lung cancer patients alive without progression. Innovent deal flagged for early-stage risk.
31 May 2026
·
Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly will acquire Curevo Inc., LimmaTech Biologics AG, and Vaccine Company Inc. for up to $3.83 billion in cash, gaining vaccine programs for shingles, staph infections, and Epstein-Barr virus. Shares rose about 5% after news of the deals and broader coverage for Zepbound and Foundayo. Curevo shareholders may receive up to $1.5 billion, LimmaTech $780 million, and Vaccine Company $1.55 billion.
28 May 2026
···
Hoth Therapeutics Changes Name to Rocket One, RKTO Stock Moves

Hoth Therapeutics Changes Name to Rocket One, RKTO Stock Moves

Rocket One Inc., formerly Hoth Therapeutics, began trading under the new Nasdaq ticker RKTO Thursday after a rebrand and pivot to AI chip technology for space. Shares jumped 47% pre-market to $1.999, following a 92% surge in the previous session. The company retains its biotech pipeline under a subsidiary but highlights early-stage tech, capital needs, and going-concern risks in filings.
28 May 2026
··
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences shares fell 37% to $0.205 Wednesday after announcing a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 and a $2 million stock offering. Trading volume topped 230 million shares. The licensing agreement is non-binding, with a potential value over $100 million, and gives Jupiter 90 days to finalize terms. Jupiter reported a $2.06 million Q1 net loss and $2.36 million in cash.
21 May 2026
···
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
20 May 2026
···
InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
20 May 2026
··
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.
19 May 2026
··
Regeneron Opens Lower After Cancer Trial Setback

Regeneron Opens Lower After Cancer Trial Setback

Regeneron shares dropped 11.8% in premarket trading Monday after its melanoma drug combo failed to meet the main goal in a late-stage trial. The high-dose fianlimab and cemiplimab combination showed a median progression-free survival of 11.5 months versus 6.4 months for Merck’s Keytruda, but missed statistical significance. Citi downgraded the stock and cut its price target to $700. Regeneron shares closed Friday at $698.25.
18 May 2026
··
Pfizer Faces Busy Week After Friday’s Drop

Pfizer Faces Busy Week After Friday’s Drop

Pfizer shares closed at $25.33 Friday, down 1.63%, underperforming the S&P 500, which fell 1.24% but still posted a weekly gain. The company reaffirmed its 2026 revenue and earnings guidance after first-quarter revenue rose 5% to $14.45 billion. Investors remain cautious, citing competitive pressure from Eli Lilly and uncertainty over Pfizer’s pipeline. U.S. markets reopen Monday.
17 May 2026
···
Pfizer Inc Looks to India, but Investors Hold Off

Pfizer Inc Looks to India, but Investors Hold Off

Pfizer is increasing investment in India for cancer drugs, obesity treatments, and vaccines as it seeks growth beyond COVID-era sales. The company reported Q1 revenue of $14.5 billion, up 5%, but expects a $1.5 billion hit this year from generic competition. Shares fell 1.8% to $25.29 in New York trading. In Europe, Pfizer won expanded approval for its hemophilia drug Hympavzi.
15 May 2026
·
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Apellis Pharmaceuticals Vanishes From Nasdaq as Biogen’s Rare-Disease Bet Takes Over

Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals, making Apellis a wholly owned subsidiary and ending its Nasdaq listing. Apellis shareholders receive $41 per share in cash plus a contingent value right tied to Syfovre sales. Biogen gains Syfovre and Empaveli, which generated $689 million in 2025 revenue. Biogen funded the deal with $2 billion in unsecured term loans.
14 May 2026
···
1 2 3 4 … 42

Stock Market Today

  • Qualcomm Shares Drop 2.05% Amid Earnings Concerns and Sector Lag
    June 22, 2026, 7:15 PM EDT. Qualcomm (QCOM) shares fell 2.05% to $221.49, underperforming the S&P 500's 0.37% decline in the latest session. The chipmaker's stock has dropped over 5% in the past month, lagging its sector's 4.52% gain and the S&P 500's 2.02% rise. Analysts expect Qualcomm's earnings per share (EPS) to fall 20.22% year-over-year to $2.21 and revenue to decline 6.46% to $9.7 billion for the quarter. The company holds a Forward P/E ratio of 21, below the industry's 53.67 average, and a high PEG ratio of 20.79, indicating expectations of slow earnings growth. Qualcomm has a Zacks Rank of #3 (Hold), reflecting cautious analyst sentiment amid a semiconductor industry ranked in the top 23% by Zacks Research.

Latest articles

Dominion Energy Faces $67 Billion Test From Virginia Data Center Power Surge

Dominion Energy Faces $67 Billion Test From Virginia Data Center Power Surge

23 June 2026
Dominion Energy shares hovered near a 52-week high as investors weighed surging Virginia data-center power demand and the pending NextEra takeover, with the stock closing at $68.04, down 0.54%; the deal’s outcome and regulatory approvals could determine whether Dominion’s capital plan becomes shareholder gains or a balance-sheet risk.
Micron Shares Reach All-Time High with AI Memory Demand in Focus Ahead of Earnings

Micron Shares Reach All-Time High with AI Memory Demand in Focus Ahead of Earnings

23 June 2026
Micron Technology surged 6.9% to a record $1,211.38 after announcing a supply and investment deal with Anthropic, defying a tech market drop, as investors bet on AI-driven demand and raised analyst targets; Wednesday’s earnings will test if Micron can sustain gross margins above 80% and meet rising expectations amid tight competition and a global memory shortage.
Go toTop